{"nct_id":"NCT07024706","title":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","status":"NOT_YET_RECRUITING","status_verified_date":"2025-08","start_date":"2025-09-30","start_date_type":"ESTIMATED","primary_completion_date":"2032-11-30","primary_completion_date_type":"ESTIMATED","completion_date":"2032-11-30","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["AZN"]}